• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Genenta Science S.p.A.

    11/14/24 4:02:59 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GNTA alert in real time by email
    6-K 1 form6-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    Under the Securities Exchange Act of 1934

     

    For the month of November 2024

     

    Commission File Number: 001-41115

     

    GENENTA SCIENCE S.P.A.

    (Translation of Registrant’s Name into English)

     

    Via Olgettina No. 58

    20132 Milan, Italy

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

    This report on Form 6-K is incorporated by reference into the registrant’s registration statement on Form F-3 (File No. 333-271901).

     

     

     

     

     

     

    Other Events

     

    AGC Letter of Intent

     

    On October 31, 2024, Genenta Science S.p.A. (“Genenta”) entered into a letter of intent (the “LOI”) with AGC Biologics S.p.A. (“AGC”), pursuant to which Genenta and AGC agreed to negotiate the terms of a development and manufacturing services agreement for Genenta’s cell therapy products (the “Proposed Agreement”) and to execute the Proposed Agreement by December 15, 2024 (the “Negotiation End Date”). Pursuant to the LOI, AGC shall: (i) reserve an exclusive GMP suite (the “EGS”) in accordance with the terms of the LOI; and (ii) commit a dedicated team of five (5) full-time employees where, upon approval of the EGS by the Agenzia Italiana del Farmaco, shall be made available for the exclusive benefit of Genenta for use in connection with the services pursuant to the Proposed Agreement. If the Proposed Agreement is not executed by the Negotiation End Date, Genenta shall pay to AGC: (i) €100,000 for the reservation of the EGS; and (ii) €140,000 per month for twelve (12) months starting from the Negotiation End Date.

     

    The above description of the LOI is qualified in its entirety by reference to the LOI, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

     

    Update Regarding Intellectual Property

     

    In April 2024, Genenta filed a patent application relating to methods of treating solid cancers with Temferon in combination with a checkpoint inhibitor and, in September 2024, Genenta filed a patent application relating to methods of treating renal cell carcinoma with Temferon in combination with a checkpoint inhibitor (together, the “Provisional Patents”). The Provisional Patents are wholly owned by Genenta.

     

    In addition, Genenta’s option rights to include three additional patent families in the license granted to Genenta under the Original License Agreement with San Raffaele Hospital (Ospedale San Raffaele or “OSR”) expired. The expiration of these option rights will not have a material adverse effect on Genenta’s business, financial condition or results of operations. Genenta is able to make Temferon without access to these patent families. The patent families to which Genenta has rights under the Amended and Restated License Agreement (“ARLA”) are set forth in the table below:

     

    Focus / Family   U.S.   E.U.   Expiration
                 
    Gene Vector comprising mi-RNA   USP 10,000,757*   EP 2002003 B1   5/26/2026*
    (composition and method of treatment claims)   USP 9,556,438        
    PCT/IB2006/002266 (WO 2007/000668).   USSN 16/004,394        
        (pending)        
                 
    Gene Vector comprising mi-RNA   USP 10,287,579   EP 2424571 B1   4/30/2030
    (composition and method of treatment claims)   USP 9,951,328   EP 20167404.1    
    PCT/IB2010/001166 (WO / 2010/125471)   USSN 16/384,571   (pending)    
        (pending)        
                 
    Type 1 Interferon Gene Therapy   USSN 16/604,484   EP 18724470.2   4/20/2038
    (method of treatment claims)            
    PCT/EP2018/060238 (WO 2018/193119)            

     

    * Later expiration for certain U.S. patents pursuant to patent term adjustment (35 U.S.C. §154(b)).

     

    Exhibits

     

    Exhibit No.   Title
         
    10.1   Letter of Intent, dated October 31, 2024, between AGC Biologics S.p.A. and Genenta Science S.r.l.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      GENENTA SCIENCE S.P.A.
         
    Date: November 14, 2024 By: /s/ Pierluigi Paracchi
        Pierluigi Paracchi, Chief Executive Officer

     

     

     

    Get the next $GNTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNTA

    DatePrice TargetRatingAnalyst
    6/29/2023$15.00Buy
    ROTH MKM
    7/25/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $GNTA
    Leadership Updates

    Live Leadership Updates

    See more
    • ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

      Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1 SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hu

      1/8/25 3:17:00 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

      5/6/24 6:25:00 AM ET
      $ARYD
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

      Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

      1/17/23 8:00:00 AM ET
      $AGRX
      $GNTA
      $NMTR
      $PG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Package Goods/Cosmetics

    $GNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM resumed coverage on Genenta S.p.A. with a new price target

      ROTH MKM resumed coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $15.00

      6/29/23 9:11:48 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Genenta S.p.A. with a new price target

      H.C. Wainwright initiated coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $25.00

      7/25/22 7:15:53 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNTA
    SEC Filings

    See more

    $GNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 424B5 filed by Genenta Science S.p.A.

      424B5 - Genenta Science S.p.A. (0001838716) (Filer)

      3/28/25 4:30:29 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 20-F filed by Genenta Science S.p.A.

      20-F - Genenta Science S.p.A. (0001838716) (Filer)

      3/28/25 4:25:59 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genenta Science S.p.A.

      6-K - Genenta Science S.p.A. (0001838716) (Filer)

      3/19/25 9:27:03 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

      SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

      2/12/24 4:05:34 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

      SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

      2/10/23 6:02:50 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Genenta Science S.p.A.

      SC 13G - Genenta Science S.p.A. (0001838716) (Subject)

      2/25/22 1:17:49 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

      MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) based in Italy. This strategic partnership marks a major milestone, encompassing the successful production of critical starting materials, including the establishment of Cell Banks and the manufacturing of Plasmids for viral vector production. This collaboration represents a pivotal step in the advancement of immuno-oncology therapies, highlighting the powerful synergy between Genenta's innovative platform and Anemocyte's proven exper

      5/7/25 7:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

      MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at "Montalcini Global Biotech Tour" in Doha, Qatar on April 17th, 2025 at the Sheikh Fahad bin Jassim Al Thani theatre, Ministry of Commerce and Industry (MOCI) Building. Following the announcement of a €20 million ($22.7 million) strategic financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) — aimed at expanding Genenta's pipeline with the advancement of Temferon™ in metastatic Renal Cell Cancer (mRCC) — and the addition of approximately €3.0 million

      4/15/25 5:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

      MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer (mRCC). ETB is a leading private foundation, supervised by the Italian Ministry of Enterprises and Made in Italy, managing over €1,7 billion in assets under management through two funds. With deep expertise in the biomedical sector, ETB is an established authority in identifying and supporting high-pote

      3/19/25 9:28:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care